1,320 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Lilly's Breast Cancer Combo Drug Phase III Results Positive http://www.zacks.com/stock/news/253465/lillys-breast-cancer-combo-drug-phase-iii-results-positive?cid=CS-ZC-FT-253465 Mar 21, 2017 - Eli Lilly and Company (LLY) recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer, met the primary endpoint of progression-free survival (PFS).
Novartis (NVS) Announces Positive Data on Heart Failure Drug http://www.zacks.com/stock/news/253425/novartis-nvs-announces-positive-data-on-heart-failure-drug?cid=CS-ZC-FT-253425 Mar 20, 2017 - Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/493765/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 20, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 20, 2017
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253074/conatus-pharma-cnat-incurs-wider-than-expected-loss-in-q4?cid=CS-ZC-FT-253074 Mar 16, 2017 - Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.
Glaxo Files for Label Expansion of Influenza Vaccine in US http://www.zacks.com/stock/news/252981/glaxo-files-for-label-expansion-of-influenza-vaccine-in-us?cid=CS-ZC-FT-252981 Mar 16, 2017 - GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/492165/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 14, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 14, 2017
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy http://www.zacks.com/stock/news/252712/novartis-breast-cancer-drug-okd-by-fda-as-first-line-therapy?cid=CS-ZC-FT-252712 Mar 14, 2017 - Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction http://www.zacks.com/stock/news/252531/aerie-resubmits-rhopressa-nda-roclatan-gains-traction?cid=CS-ZC-FT-252531 Mar 13, 2017 - Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
How Incyte Stock Became a Bull Market Star for Biotech Investors http://www.zacks.com/stock/news/252365/how-incyte-stock-became-a-bull-market-star-for-biotech-investors?cid=CS-ZC-FT-252365 Mar 10, 2017 - Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/490792/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 09, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 09, 2017
<<<Page 123>